Kadimastem - Stem Cell to Cure Diseases

News & Events > Press Releases

Success for Kadimastem in Rights Offering;

Feb. 28, 2017
Raised NIS 7.2M 71% of the rights offered were exercised

Kadimastem Announces Strategic Collaboration with Korean Biotech Company Corestem, Including a $7M Investment in Kadimastem

Dec. 7, 2016
Corestem is the only company in the world with a cell therapy treatment for ALS which has been approved for marketing by a regulatory authority. Corestem believes in Kadimastem's technologies in the ALS and diabetes fields, and the agreement will assist in expediting Kadimastem's entry into the market

Stakeholders' Support for Kadimastem Continues: Investment of NIS 2.5M by Way of Convertible Loan

Nov. 9, 2016
If an investment agreement of $ 2M or more will be signed with a foreign company or investor, the loan will be converted in a rights offering under identical terms

Towards the Company's First Clinical Trial;

Nov. 2, 2016
Kadimastem Signs Letter of Intent with Hadassah Medical Center for Performance of the Clinical Trial in ALS

Press Releases Archive